Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency

Ítems similars

• SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
  per: Maniatis, Aristides K, et al.
  Publicat: (2020)
• OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
  per: Thornton, Paul, et al.
  Publicat: (2019)
• Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
  per: Fleseriu, Maria, et al.
  Publicat: (2021)
• OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
  per: Maniatis, Aristides K, et al.
  Publicat: (2020)
• The Role of the hGH Locus Control Region in Somatotrope Restriction of hGH-N Gene Expression
  per: Ho, Yugong, et al.
  Publicat: (2011)